Medine.co.uk

Nutrition Warehouse Herbal Travel Sickness Tablets

Informations for option: Nutrition Warehouse Herbal Travel Sickness Tablets, show other option

SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

•    Nutrition Warehouse Herbal Travel Sickness Tablets

•    Holland & Barrett Herbal Travel Sickness Tablets

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each Tablet contains:

250mg Ginger Rhizome (Zingiber officinale ROSCOE)

For full list of excipients, see section 6.1

3 PHARMACEUTICAL FORM

Tablet

Light brown oval biconvex tablet.

4    CLINICAL PARTICULARS

4.1    Therapeutic indications

Traditional herbal medicinal product used for the symptomatic relief of travel sickness, based on traditional use only.

4.2 Posology and method of administration

For oral use only.

The tablets should be swallowed whole with 1-2 glasses of water. Do not chew the tablets.

Adults, the elderly and children over 12 years:

3 tablets to be taken with water 30 minutes before travelling.

Children under 12 years of age:

The use in children and adolescents under 12 years of age is not recommended (see section 4.4 ‘Special warnings and precautions for use’).

Duration of use

If the symptoms persist for more than 5 days or worsen during the use of the product, a doctor or qualified health care practitioner should be consulted.

4.3 Contraindications

Hypersensitivity to the active substance or any of the excipients.

Peptic or duodenal ulcer.

Obstruction of the bile duct, cholangitis or gall stones.

4.4 Special warnings and precautions for use

Do not exceed the stated dose.

Ginger may inhibit platelet aggregation and may decrease platelet thromboxane production thus, theoretically, may increase the risk of bleeding.

The product should be discontinued at least 2 weeks prior to elective surgery due to the potential increased risk of bleeding and for potential interactions with medicinal products used during general and regional anaesthesia. (See Section 4.5)

The use in children and adolescents under 12 years of age is not recommended due to the lack of data on safety and efficacy.

If the symptoms persist for more than 5 days or worsen during the use of the product, a doctor or qualified health care practitioner should be consulted.

4.5 Interaction with other medicinal products and other forms of interaction

Ginger may increase the risk of bleeding when taken with drugs that affect coagulation and bleeding eg. Aspirin, anticoagulants such as warfarin, phenprocoumon, heparin, antiplatelet drugs such as clopidogrel, and non-steroidal anti-inflammatory drugs such as aspirin, ibuprofen and naproxen.

4.6 Fertility, pregnancy and lactation

Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended.

Studies on the effects on fertility have not been performed.

4.7 Effects on ability to drive and use machines

No studies on the effect on the ability to drive and use machines have been performed.

In some cases patients have experienced drowsiness while taking ginger. Affected patients should not drive or operate machinery.

4.8 Undesirable effects

Minor gastrointestinal complaints including stomach upset, heartburn, eructation, bloating, flatulence, nausea, dyspepsia. Frequency 2-3%.

Drowsiness has also been reported.

There is one case report of inhibition of platelet aggregation following chronic consumption of large quantities of ginger marmalade. There is one case report of potential interaction with warfarin (see Section 4.5)

If other reactions not mentioned above occur, a doctor or qualified health care practitioner should be consulted.

4.9 Overdose

No cases of overdose have not been reported.

Supportive and symptomatic treatment should be provided as appropriate.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.2 Pharmacokinetic properties

Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.3 Preclinical safety data

Adequate tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.

6    PHARMACEUTICAL PARTICULARS

6.1    List of excipients

Calcium Phosphate Tribasic Calcium Sulphate Dihydrate Potato Starch Vegetable Fatty Acid Calcium Phosphate Dibasic Ethylcellulose N100

6.2 Incompatibilities

None known.

6.3 Shelf life

3 years

6.4 Special precautions for storage

Do not store above 25°C.

Store in the original package.

6.5 Nature and contents of container

Blister pack of hard tempered aluminium foil and food quality PVC enclosed in cardboard outer.

Pack size: 30 tablets.

6.6 Special precautions for disposal

No special requirements.

7 MARKETING AUTHORISATION HOLDER

Nutrition Warehouse Limited

Samuel Ryder House

Barling Way

Eliot Park

Nuneaton

Warwickshire

CV10 7RH

United Kingdom

8    MARKETING AUTHORISATION NUMBER(S)

THR 14010/0044

9    DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

19/03/2013

10    DATE OF REVISION OF THE TEXT

19/03/2013